Boston-based Verve Therapeuticss’ study for its one-time drug treatment found patients treated with possible therapeutic doses had between a 39% and 55% reduction in LDL cholesterol.
A second drug, lepodisiran, reduced the harmful risk factor lipoprotein(a) by 94%. The reductions lasted nearly a year, according to the phase 1 study published in the Journal of the American Medical Association. Lp(a) is a form of cholesterol with characteristics in common with LDL cholesterol, according to a Nov. 12 American Heart Association news release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
